New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
09:32 EDTNYMXNymox announces positive efficacy results in Phase 3 trial of NX-1207
Nymox announced new positive efficacy data for U.S. Study NX02-0022, the company's repeat injection study of NX-1207 for BPH. Analysis of symptomatic improvement from repeat injection over a 1 to 2 year period showed a mean improvement of 8.2 points in the AUA BPH Symptom Index Score. Evaluation of safety data from this study confirmed that NX-1207 reinjection treatment was well-tolerated by patients, did not impair sexual function, and has not shown any drug-related significant side effects. Participants in the clinical trial consisted of 160 consecutively treated men who had previously completed participation in an NX-1207 trial for BPH and who volunteered for a subsequent open label injection of NX-1207.
News For NYMX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for NYMX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use